Prakiraan wutah bathi kanggo taun ngarep scisparc.com (SPRC)

Demand for pharmaceuticals remains stable, although geopolitics and sanctions complicate raw material logistics. The development of unique cannabinoid treatments for the CNS provides SciSparc Ltd (SPRC) opportunities for market dominance. The target net income per share growth rate reflects the impact of these factors, with the metric holding at 0.00. The company is currently battling a liquidity shortage, cutting expenses due to costly clinical trials.

Clearmind Medicine (SPRC): Prakiraan wutah bathi resik saben saham ing taun ngarep saka 21.02.2024 nganti 15.11.2026

Rincian analitis perusahaan SciSparc Ltd

- rega saham lan konsensus proyeksi valuasi:

Rega saham scisparc.com|SPRC - Target konsensus

- rincian kapitalisasi pasar:

Kapitalisasi pasar Clearmind Medicine|SPRC - Nilai Dipunlarasaken Utang lan Kas

- indikator kapitalisasi buku:

Aset Bersih saben Siji Saham SciSparc|SPRC - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku scisparc.com|SPRC - Gunggung Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- data bathi resik lan rasio valuasi:

SPRC - Bathi resik|Bathi sing dikarepake SciSparc Ltd|SPRC - Nilai perusahaan marang bathi resik|Pangali Forward P/E SciSparc Ltd.|SPRC - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Clearmind Medicine|SPRC - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan SciSparc|SPRC - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan scisparc.com|SPRC - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep SciSparc Ltd

- data total pendapatan lan volume dodolan:

SPRC - Volume dodolan perusahaan|Prakiraan pendapatan perusahaan scisparc.com|SPRC - Koefisien rega marang pendapatan|Rasio rega marang prakiraan pendapatan SciSparc Ltd.

Analisis wiwitan perusahaan:SPRC, scisparc.com

The indicator calculates the expected percentage growth of net earnings per share based on consolidated analyst forecasts and current financial reporting data. This metric determines the fairness of the market valuation of SciSparc Ltd (SPRC), where inertial demand for CNS therapy drugs guarantees revenue stability, as reflected in the trend of the company's forward EPS estimates.

Analisis pesaing